Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers, Moderna und Roche ziehen Anti Virus-Index auf Jahreshoch

Der Global Anti Virus Health Net Return Index hat in den zurückliegenden Tagen von der Mehrheit der Indexmitglieder Rückenwind erhalten.…

Societe Generale cuts Bristol-Myers Squibb to Hold By Investing.com

Societe Generale cuts Bristol-Myers Squibb to Hold…

Bristol-Myers Squibb: Finally Trending Up

…

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024, Featuring Sanofi, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical and Amgen

Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024" has…

Bristol-Myers Squibb: Turnaround Expected

…

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

…

Bristol-Myers Squibb Company (BMY) 44th Annual TD Cowen Healthcare Conference (Transcript)

…

Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol-Myers Squibb

The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in…

Bristol Myers Squibb completes RayzeBio acquisition By Investing.com

Bristol Myers Squibb completes RayzeBio acquisition…

Bristol Myers Squibb nears RayzeBio acquisition completion By Investing.com

Bristol Myers Squibb nears RayzeBio acquisition completion…

This $674 Million Deal Aims To Turn Your Bodys Garbage Disposal Into A Disease Fighter

VantAI has inked a partnership with pharma giant Bristol Myers Squibb that hopes to use the body’s cellular waste disposal…

How This Top 2% Biotech Overcame Two Obstacles And Doubled

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.…

Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing

The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.…

Redburn cuts Bristol-Myers Squibb price target to $54 By Investing.com

Redburn cuts Bristol-Myers Squibb price target to $54…

FDA to review expanded use of Bristol Myers Squibbs Abecma By Investing.com

FDA to review expanded use of Bristol Myers Squibbs Abecma…

Bristol-Myers Squibb: All Focus On Execution

…

Bristol-Myers Squibb: Massive Discount Spells Opportunity

…

Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript

BMY earnings call for the period ending December 31, 2023.…

Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation

…

Bristol-Myers Squibb Company (BMY) Q4 2023 Earnings Call Transcript

…

Bristol Meyers Squibb, AbbVie top 4Q sales and profit estimates

Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results...…

Stocks making the biggest premarket moves: Meta, Amazon, Bristol-Myers Squibb, Chevron and more

These are the stocks posting the largest moves in the premarket.…

Bristol-Myers Squibb beats in Q4 as Eliquis and Opdivo outperform

…

Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales By Investing.com

Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales…

Bristol-Myers Squibb earnings beat by $0.10, revenue topped estimates By Investing.com

Bristol-Myers Squibb earnings beat by $0.10, revenue topped estimates…

Bristol Myers Squibb results top expectations as newer drugs help fuel growth

Bristol Myers Squibb on Friday reported fourth-quarter results that beat analysts’ expectations, helped by portfolio stalwarts as well as newer…

Bristol Myers Squibb results top estimates as new drugs post strong sales growth

Bristol Myers Squibb also issued its full-year 2024 forecast, which was generally in line with expectations.…

Antibiotics Market revenue to surpass USD 108 Billion by 2035, says Research Nester

Major antibiotics market players include F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Abbott Laboratories, Merck…

Bayer und Eli Lilly: Heißer Markt

Der Markt für Radiopharmaka bleibt für große Player von Interesse. Das haben die jüngsten Übernahmen von Rayzebio (durch Bristol Myers…

Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat

J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for…

Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices

The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen.…

Bristol-Myers Squibb: Dont Waver Over Undue Fears And Doubts

…

Is Bristol Myers Squibb Stock a Buy Now?

This healthcare stock has seen healthier days.…

Melanoma Drugs - $13.98 Billion Industry Opportunity Assessment, 2024-2028: Regional Insights and Competitor Market Shares

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Melanoma Drugs Global Market Report 2024" report has been added…

Bristol Myers Squibb: Might Be Approaching A Bottom In 2024

…

Biotech Market Forecast: Top Trends That Will Affect Biotech in 2024

The biotech sector is a dynamic and constantly evolving industry that is driving scientific advancements and innovation in healthcare. According…

A Rare And Major Dividend Stock Buying Opportunity With Altria And Bristol Myers Squibb

…

Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal

…

NHWK: Transformational Changes

By John Vandermosten, CFA NYSE:NHWK NightHawk Biosciences, Inc. (NYSE:NHWK) reported 3Q:23 results on November 20th, 2023 as published in a press release…

AstraZeneca: Rebound in 2024 With Double-Digit Earnings Growth

Stocks Analysis by MarketBeat.com (Kate Stalter) covering: Eli Lilly and Company, Merck & Company Inc, Pfizer Inc, Bristol-Myers Squibb Company.…

Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also

…

Bile Duct Cancer Treatment Market Trends and Forecast 2031 - Market Set for Significant Growth by 2031 Amid Rising Incidences and Technological Advancements

Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Bile Duct Cancer Treatment Market - Global Industry Analysis, Size,…

Bristol-Myers CEO talks new acquisitions: We are writing the next chapter of this company

Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giants slew of recent acquisitions in a Monday interview with CNBCs Jim…

Bristol-Myers Squibb Company (BMY) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

PRTG: Bridging I-O: Working in Harmony with Checkpoints

By John Vandermosten, CFA NASDAQ:PRTG READ THE FULL PRTG RESEARCH REPORT We are initiating coverage of Portage Biotech Inc. (NASDAQ:PRTG) with a target…

Evotec: Neue Meilensteinzahlung treibt Aktie an

Trotz des kürzlichen CEO-Wechsels zeigt die Evotec-Aktie Anzeichen einer Erholung. Unterstützend wirkt dabei eine Meilensteinzahlung von Bristol-Myers Squibb.…

Evotec auf Erholungskurs: BMS-Deal zahlt sich aus

Die Aktie von Evotec befindet sich nach dem Einbruch von vergangener Woche wieder auf Erholungskurs. Das Papier gewinnt am Vormittag…

ROUNDUP: Evotec erhält Meilensteinzahlung aus Partnerschaft mit BMS - Kursplus

HAMBURG (dpa-AFX) - Die Zusammenarbeit des Wirkstoffforschers und -entwicklers Evotec mit dem US-Pharmakonzern Bristol Myers Squibb (BMS) trägt…

ANALYSE-FLASH: RBC belässt Evotec auf Sector Perform - Ziel 18,60 Euro

NEW YORK (dpa-AFX Broker) - Die kanadische Bank RBC hat Evotec auf "Sector Perform" mit einem Kursziel von 18,60…

EVOTEC SE Sector Perform

NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Evotec auf "Sector Perform" mit einem Kursziel von 18,60 Euro…